Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: A randomized, double-blind, cross-over investigation in obese persons

European Journal of Clinical Nutrition

Volumn 66, Issue 5, 2012, Pages 585-590

  Andersson, U ^a   Berger, K ^a   Hogberg A ^b   Landin Olsson, M ^c   Holm, C ^a  

^a LUND UNIVERSITY   (Sweden)

^b Orkla ASA ^*  (Norway)

^c LUND UNIVERSITY   (Sweden)

Author keywords

blood pressure; body weight; cholesterol; glucose tolerance; inflammation

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BEVERAGE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; ROSE HIP DRINK; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FRUIT; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; OBESITY; PHYTOTHERAPY; PLANT PREPARATIONS; RISK ASSESSMENT; RISK FACTORS; ROSA;

MUS;

EID: 84860630996     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2011.203     Document Type: Article

References (31)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87, 4-14.
2. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010; 1801, 209-214.
3. Shoelson SE, Goldfine AB. Getting away from glucose: Fanning the flames of obesity-induced inflammation. Nat Med 2009; 15, 373-374.
4. Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 2009; 9, 737-743.
5. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53, 1270-1287.
6. Chrubasik C, Roufogalis BD, Muller-Ladner U, Chrubasik S. A systematic review on the Rosa canina effect and efficacy profiles. Phytother Res 2008; 22, 725-733.
7. Kharazmi A, Winther K. Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo. Inflammopharmacology 1999; 7, 377-386.
8. Winther K, Apel K, Thamsborg G. A powder made from seeds and shells of a rosehip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol 2005; 34, 302-308.
9. Winther K, Rein E, Kharazmi A. The anti-inflammatory properties of rose-hip. Inflammopharmacology 1999; 7, 63-68.
10. Jager AK, Eldeen IM, van Staden J. COX-1 and -2 activity of rose hip. Phytother Res 2007; 21, 1251-1252.
11. Willich SN, Rossnagel K, Roll S, Wagner A, Mune O, Erlendson J et al. Rose hip herbal remedy in patients with rheumatoid arthritis - A randomised controlled trial. Phytomedicine 2010; 17, 87-93.
12. Ninomiya K, Matsuda H, Kubo M, Morikawa T, Nishida N, Yoshikawa M. Potent anti-obese principle from Rosa canina: Structural requirements and mode of action of trans-tiliroside. Bioorg Med Chem Lett 2007; 17, 3059-3064.
13. Andersson U, Henriksson E, Strom K, Alenfall J, Goransson O, Holm C. Rose hip exerts antidiabetic effects via a mechanism involving downregulation of the hepatic lipogenic program. Am J Physiol Endocrinol Metab 2011; 300, E111-E121.
14. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007; 297, 611-619.
15. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men. Circulation 2008; 118, 2243-2251, 4p following 51.
16. Hunninghake DB, Miller VT, LaRosa JC, Kinosian B, Jacobson T, Brown V et al. Long-term treatment of hypercholesterolemia with dietary fiber. Am J Med 1994; 97, 504-508.
17. Hendriks H.F. Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr 2003; 57, 681- 692.
18. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333, 1308-1312.
19. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78, 965-978.
20. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290, 502-510.
21. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82, 1916-1924.
22. Bukowska H, Pieczul-Mroz J, Jastrzebska M, Chelstowski K, Naruszewicz M. Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarum in subjects with moderately elevated cholesterol. Atherosclerosis 1998; 137, 437-438.
23. Rein E, Kharazmi A, Winther K. A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis-a double-blind, placebo-controlled, randomised trial. Phytomedicine 2004; 11, 383-391.
24. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338, b1665.
25. Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002; 76, 1249-1255.
26. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: A meta-analysis of randomized, controlled clinical trials. J Hypertens 2005; 23, 475-481.
27. Streppel MT, Arends LR, van 't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: A meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005; 165, 150-156.
28. Warholm O, Skaar S, Hedman E, Moelmer H, Eik L. The effect of a standardized herbal remedy made from a subtype of rosa canina in patients with osteoarthritis: A double-blind, randomized, placebo-controlled clinical trial. Curr Ther Res 2003; 64, 21-31.
29. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res 2007; 21, 675-683.
30. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375, 735-742.
31. Jenkins DJ, Kendall CW, Faulkner DA, Nguyen T, Kemp T, Marchie A et al. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr 2006; 83, 582-591.